戻る
Vor Biopharma Inc (VOR) 収入
VOR 株価推移チャート
VOR 収入
Vor Biopharma Inc
$18.05
3.79%
$0.66
終値： Apr 02, 16:00:00 GMT-4
$18.41
1.99%
$0.35
アフターマーケット：Apr 02, 17:09:34 GMT-4
最新の利益結果: Q3 '25
報告済み: 2025-11-13
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
VORの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Vor Biopharma Inc VORの前四半期の収益はどうでしたか？
Vor Biopharma Incの収益見積もりはいくらですか？
Vor Biopharma Incの収益品質スコアはどれくらいですか？
Vor Biopharma Incはいつ収益を報告しますか？
Vor Biopharma Incの予想収益はいくらですか？
Vor Biopharma Incは収益予想を上回りましたか？
主要データ
前終値
$17.39
始値
$17.04
当日レンジ
$16.76 - $19.3
52週レンジ
$2.62 - $65.8
取引高
1.5M
平均取引高
966.6K
配当利回り
--
1株当たり利益(TTM)
-386.85
時価総額
$764.3M
VORとは何ですか？
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 159 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.